Opko Health Inc. (NYSE:OPK)’s share price traded down 2.9% during trading on Tuesday . The stock traded as low as $9.37 and last traded at $9.52, with a volume of 3,760,140 shares changing hands. The stock had previously closed at $9.80.

Several equities analysts recently commented on the company. Ladenburg Thalmann reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, April 27th. Standpoint Research began coverage on Opko Health in a research report on Friday, June 3rd. They set a “buy” rating and a $16.00 target price on the stock. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Opko Health in a research report on Tuesday, May 31st. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Opko Health currently has an average rating of “Buy” and an average target price of $14.05.

The firm has a 50-day moving average of $9.92 and a 200-day moving average of $9.96. The stock has a market cap of $5.24 billion and a PE ratio of 39.83.

Opko Health (NYSE:OPK) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to the consensus estimate of $324.11 million. During the same period last year, the business earned ($0.09) EPS. Opko Health’s revenue was up 742.2% on a year-over-year basis. Equities analysts expect that Opko Health Inc. will post ($0.05) EPS for the current year.

In related news, CEO Phillip Md Et Al Frost bought 20,000 shares of the business’s stock in a transaction on Friday, May 27th. The stock was acquired at an average price of $10.35 per share, with a total value of $207,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $31,763,642.85. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently raised its position in Opko Health stock. Coe Capital Management LLC raised its stake in Opko Health Inc. (NYSE:OPK) by 45.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 199,400 shares of the company’s stock after buying an additional 62,400 shares during the period. Coe Capital Management LLC’s holdings in Opko Health were worth $2,004,000 at the end of the most recent quarter.

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.